Artelo Biosciences (ARTL) Competitors $5.05 +0.37 (+7.91%) As of 01:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARTL vs. ENLV, ALLR, NAII, PASG, NNVC, NEUP, SONN, SNYR, CTXR, and RLYBShould you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include Enlivex Therapeutics (ENLV), Allarity Therapeutics (ALLR), Natural Alternatives International (NAII), Passage Bio (PASG), NanoViricides (NNVC), Neuphoria Therapeutics (NEUP), Sonnet BioTherapeutics (SONN), Synergy CHC (SNYR), Citius Pharmaceuticals (CTXR), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry. Artelo Biosciences vs. Its Competitors Enlivex Therapeutics Allarity Therapeutics Natural Alternatives International Passage Bio NanoViricides Neuphoria Therapeutics Sonnet BioTherapeutics Synergy CHC Citius Pharmaceuticals Rallybio Artelo Biosciences (NASDAQ:ARTL) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Which has more risk and volatility, ARTL or ENLV? Artelo Biosciences has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Does the media prefer ARTL or ENLV? In the previous week, Artelo Biosciences had 3 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 13 mentions for Artelo Biosciences and 10 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.89 beat Artelo Biosciences' score of 0.18 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artelo Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enlivex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ARTL or ENLV more profitable? Enlivex Therapeutics' return on equity of -58.31% beat Artelo Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Artelo BiosciencesN/A -497.68% -213.76% Enlivex Therapeutics N/A -58.31%-50.32% Do institutionals and insiders hold more shares of ARTL or ENLV? 0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 5.8% of Artelo Biosciences shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer ARTL or ENLV? Artelo Biosciences presently has a consensus price target of $24.00, suggesting a potential upside of 375.25%. Enlivex Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 885.22%. Given Enlivex Therapeutics' higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Artelo Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, ARTL or ENLV? Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtelo BiosciencesN/AN/A-$9.83M-$19.05-0.27Enlivex TherapeuticsN/AN/A-$15.01M-$0.58-1.75 SummaryEnlivex Therapeutics beats Artelo Biosciences on 8 of the 13 factors compared between the two stocks. Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTL vs. The Competition Export to ExcelMetricArtelo BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.56M$3.15B$5.76B$10.07BDividend YieldN/A2.28%5.28%4.52%P/E Ratio-0.2721.3375.5226.24Price / SalesN/A425.78516.30171.25Price / CashN/A45.5837.2059.76Price / Book0.959.6611.576.22Net Income-$9.83M-$53.33M$3.28B$270.65M7 Day Performance-42.35%1.32%1.08%3.11%1 Month Performance-39.52%11.96%11.26%9.04%1 Year Performance-26.81%13.36%62.17%27.90% Artelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTLArtelo Biosciences2.6464 of 5 stars$5.05+7.9%$24.00+375.2%-38.1%$3.56MN/A-0.275News CoverageAnalyst ForecastENLVEnlivex Therapeutics3.3114 of 5 stars$1.04-1.0%$10.00+861.5%-14.2%$24.60MN/A-1.5870News CoverageALLRAllarity Therapeutics2.382 of 5 stars$1.66+7.5%$9.00+443.8%-56.4%$24.05MN/A0.0010NAIINatural Alternatives InternationalN/A$3.80+6.1%N/A-51.5%$23.48M$113.80M-2.73290PASGPassage Bio2.869 of 5 stars$7.12-0.2%$91.75+1,188.8%-51.9%$22.54MN/A-0.39130NNVCNanoViricides0.647 of 5 stars$1.39flatN/A-5.2%$22.34MN/A-1.9320News CoverageNEUPNeuphoria Therapeutics1.4316 of 5 stars$11.79+4.1%$21.00+78.1%N/A$22.17M$10K0.00N/ASONNSonnet BioTherapeutics1.6304 of 5 stars$3.19-1.8%$20.00+527.0%-55.2%$22.10M$20K0.0010Gap UpSNYRSynergy CHC3.8217 of 5 stars$2.33-3.7%$10.00+329.2%N/A$22.00M$34.83M6.1340CTXRCitius Pharmaceuticals2.4352 of 5 stars$1.29-3.4%$53.00+4,024.5%-90.8%$21.86MN/A0.0020News CoverageRLYBRallybio2.5835 of 5 stars$0.52-4.0%$5.00+870.9%-47.5%$21.52M$640K-0.5540 Related Companies and Tools Related Companies Enlivex Therapeutics Alternatives Allarity Therapeutics Alternatives Natural Alternatives International Alternatives Passage Bio Alternatives NanoViricides Alternatives Neuphoria Therapeutics Alternatives Sonnet BioTherapeutics Alternatives Synergy CHC Alternatives Citius Pharmaceuticals Alternatives Rallybio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTL) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredThe Obscure Korean War Act That Created a $5.39 Billion Passive Income StreamAn obscure Korean War law has just been enacted by the U.S. government... Allowing it to take a heavy hand ...Angel Publishing | SponsoredLitecoin’s Creator Backs the World’s First TreasuryBitcoin's corporate adoption story has been written. Litecoin's is just beginning.The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
